Abstract
T cells engineered with chimeric antigen receptors (CARs) are emerging as powerful cancer immunotherapies. Remarkable efficacies have been demonstrated in treating B-cell malignancies with CAR-T cells, leading to the FDA’s first approval of gene therapy. Currently, numerous clinical trials for hematological malignancies and solid tumors are underway worldwide. Production of CAR-T cells with proper qualities is essential for CAR-T success in vivo. Here we detail optimized protocols for the generation of CAR-T cells for preclinical studies using lentiviral gene transfer, expansion of CAR-T cells in culture, detection of CAR expression, and evaluation of CAR-T cellular cytotoxicity in vitro.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Sadelian M, Brentjens R, Rivière I (2013) The basic principles of chimeric antigen receptor design. Cancer Discov 3:388–398
Dotti G, Gottschalk S, Savoldo B et al (2014) Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunol Rev 257:107–126
Chmielewski M, Hombach AA, Abken H (2013) Antigen-specific T-cell activation independently of the MHC: chimeric antigen receptor-redirected T cells. Front Immunol 4:371
Jorritsma A, Gomez-Eerland R, Dokter M et al (2007) Selecting highly affine and well-expressed TCRs for gene therapy of melanoma. Blood 110:3564–3572
Maude SL, Frey N, Shaw PA et al (2014) Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 371:1507–1517
Davila ML, Riviere I, Wang X et al (2014) Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med 6:224ra25
Schuster SJ, Svoboda J, Nasta S et al (2015) Phase IIa trial of chimeric antigen receptor modified T cells directed against CD19 (CTL019) in patients with relapsed or refractory CD19+ lymphomas. J Clin Oncol 33(suppl 15):8516
Porter DL, Hwang WT, Frey NV et al (2015) Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med 7:303ra139
Maus MV, June C (2016) Making better chimeric antigen receptors for adoptive T-cell therapy. Clin Cancer Res 22:1875–1884
Jackson HJ, Rafiq S, Brentjens RJ (2016) Driving CAR T-cells forward. Nat Rev Clin Oncol 13:370–383
Suerth JD, Schambach A, Baum C (2012) Genetic modification of lymphocytes by retrovirus-based vectors. Curr Opin Immunol 24:598–608
Circosta P, Granziero L, Follenzi A et al (2009) T Cell Receptor (TCR) gene transfer with lentiviral vectors allows efficient redirection of tumor specificity in naive and memory T cells without prior stimulation of endogeouns TCR. Hum Gene Ther 20:1576–1588
Cavalieri S, Cazzaniga S, Geuna M et al (2003) Human T lymphocytes transduced by lentiviral vectors in the absence of TCR activation maintain an intact immune competence. Blood 102:497–505
Biffi A, Bartolomae CC, Cesana D et al (2011) Lentiviral vector common integration sites in preclinical models and a clinical trial reflect a benign integration bias and not oncogenic selection. Blood 117:5332–5339
Maiti SN, Huls H, Singh H et al (2013) Sleeping beauty system to redirect T-cell specificity for human applications. J Immunother 36:112–123
Kenderian SS, Ruella M, Shestova O et al (2015) CD33 specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia. Leukemia 29:1637–1647
Kochenderfer JN, Feldman SA, Zhao Y et al (2009) Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor. J Immunother 32:689–702
Kim JV, Latouche JB, Rivière I et al (2004) The ABCs of artificial antigen presentation. Nat Biotechnol 22:403–410
Kochenderfer JN, Dudley ME, Kassim SH et al (2015) Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T-cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol 33:540–549
Maus MV, Grupp SA, Porter DL et al (2014) Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood 123:2625–2635
Zheng Z, Chinnasamy N, Morgan RA (2012) Protein L: a novel reagent for the detection of Chimeric Antigen Receptor (CAR) expression by flow cytometry. J Transl Med 10:29
Jena B, Maiti S, Huls H et al (2013) Chimeric antigen receptor (CAR)-specific monoclonal antibody to detect CD19-specific T cells in clinical trials. PLoS One 8(3):e578388
Berahovich R, Xu S, Zhou H (2017) FLAG-tagged CD19-specific CAR-T cells eliminate CD19-bearing solid tumor cells in vitro and in vivo. Front Biosci–Landmrk 22:1644–1654
Irving BA, Weiss A (1991) The cytoplasmic domain of the T cell receptor zeta chain is sufficient to couple to receptor-associated signal transduction pathways. Cell 64:891–901
Decker T, Lohmann-Matthes ML (1988) A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity. J Immunol Methods 115:61–69
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Xu, Q. et al. (2019). Generation of CAR-T Cells for Cancer Immunotherapy. In: López-Soto, A., Folgueras, A. (eds) Cancer Immunosurveillance. Methods in Molecular Biology, vol 1884. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-8885-3_24
Download citation
DOI: https://doi.org/10.1007/978-1-4939-8885-3_24
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-8884-6
Online ISBN: 978-1-4939-8885-3
eBook Packages: Springer Protocols